Cart
sales@molnova.com
KER047
CAS No. 2248154-85-8
KER047( —— )
Catalog No. M35153 CAS No. 2248154-85-8
KER047 (ALK2-IN-4) is an ALK2 inhibitor with potential anticancer activity and can be used in the study of non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 250 | In Stock |
|
| 5MG | 227 | In Stock |
|
| 10MG | 369 | In Stock |
|
| 25MG | 753 | In Stock |
|
| 50MG | 1051 | In Stock |
|
| 100MG | 1609 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKER047
-
NoteResearch use only, not for human use.
-
Brief DescriptionKER047 (ALK2-IN-4) is an ALK2 inhibitor with potential anticancer activity and can be used in the study of non-small cell lung cancer.
-
DescriptionALK2-IN-4 is a potent ALK2 inhibitor extracted from patent WO2020086963A1, compound Formula I free base.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2248154-85-8
-
Formula Weight475.56
-
Molecular FormulaC26H30FN7O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 10 mg/mL (21.03 mM; Ultrasonic )
-
SMILESCOc1cc2c(ccnc2cc1F)-c1cnn2cc(cnc12)N1CCC(CC1)N1CCN(C)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sarah Bethune, et al. Crystal forms of an alk2 inhibitor. WO2020086963A1.
molnova catalog
related products
-
CPI-169
CPI-169 is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.
-
SB-505124
SB505124 is a selective inhibitor of TGFβR for ALK4, ALK5 with IC50 of 129 nM and 47 nM in cell-free assays, respectively, also inhibits ALK7, but does not inhibit ALK1, 2, 3, or 6.
-
LDN212854
LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors.
